22 August 2017
Visiongain’s new report Global Angioplasty Balloons Market 2017-2027: Revenue Prospects by Product Type (Normal, Drug-Eluting, Cutting & Scoring Balloons), Application (Coronary Artery Disease, Peripheral Artery Diseases) and Geography indicates that the Balloon Angioplasty market will see over $2.6bn in revenue in 2017.
The lead analyst of the report said:
“Balloon angioplasty is a medical procedure to open up the arteries narrowed by plaques. Increasing adoption of balloon angioplasty due to the fact that it is safe, minimally invasive and economical as compared to other surgical procedures is a key driver for growth of the market.
Presently, balloon angioplasty is a commonly performed procedure and is now considered as a standard procedure performed for coronary and peripheral artery diseases. Globally, more than two hundred million people were affected by peripheral artery diseases (PAD) in 2010. According to the Centre for Population Health Sciences at the University of Edinburgh in Scotland, the global prevalence of PAD has increased by 24% from 2000 to 2010 and it is anticipated to grow further during the forecast period. Hence, higher incidence of PAD and coronary artery diseases (CAD) are major factors driving the market in 2016.
The market is expected to observe significant growth during the forecast period from 2017-2027. This is attributed to advancements in the angioplasty field, increasing adoption of these newer technologies, and approval & launch of various angioplasty balloons. Furthermore, increasing incidence of cardiovascular and peripheral arterial diseases, rising healthcare expenditure in emerging countries and the increasing geriatric population are likely to drive the market.”
The 131-page report contains 94 tables, charts and graphs that add visual analysis in order to explain developing trends within the Angioplasty Balloon market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading Angioplasty Balloons submarkets, segmented by product type, with forecasts for Normal, Drug-Eluting, Cutting and Scoring Balloons. The market is also segmented by application, with forecasts for Coronary Artery Disease, Peripheral Artery Diseases.
The 131-page report offers market forecasts and analysis for 12 national markets. In addition, the report contains a dedicated leading companies’ chapter covering 9 companies leading the Angioplasty Balloon field in detail.
The Global Angioplasty Balloons Market 2017-2027: Revenue Prospects by Product Type (Normal, Drug-Eluting, Cutting & Scoring Balloons), Application (Coronary Artery Disease, Peripheral Artery Diseases) and Geography report will be of value to anyone who wants to better understand the angioplasty balloon market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the angioplasty balloon industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Some of the major factors fuelling the growth of global market include significant advantages associated with PIM solutions and inclination towards centralized models among across pharma sector.
19 October 2020
The coronavirus outbreak has negatively impacted all the economies and industries across the globe. Hence, for the next 1-2 years, the global respiratory drug delivery market is expected to take a hit.
12 October 2020
We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
02 October 2020
The development of mRNA vaccines is driven by new biotechnologies and nanotechnologies. Emerging delivery technologies, such as electroporation (EP), innovative vaccine formats like mRNA preventive boost, and new molecular adjuvant technologies are particularly important for mRNA vaccines reaching their potential.